Automatic Website Traffic RSS

Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor use

Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, the newcomer boasts an FDA approval covering a broader patient population. | Another drug ... read more

Day One Marks Milestone in Pediatric Cancer as Tovorafenib Approved in BRAF-Mutated Low-Grade Glioma

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms. read more

New Targeted Drug Approved for Low-Grade Glioma in Kids

It represents the first systemic therapy for pediatric low-grade gliomas harboring BRAF rearrangements, or fusions, according to the agency; the drug is also indicated for tumors with BRAF V600 ... read more

Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair

Day One Biopharmaceuticals won accelerated approval for pediatric brain cancer drug, Ojemda, with a potential market of around $1bn. Click for my DAWN update. read more

Ojemba Approved for Relapsed/Refractory BRAF-Altered Pediatric Low-Grade Glioma

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ... read more

FDA Grants Accelerated Approval to Day One’s Ojemda for Relapsed or Refractory Pediatric Low-Grade Glioma

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation. read more

US FDA grants accelerated approval to Day One Biopharma’s tovorafenib to treat relapsed or refractory BRAF-altered paediatric low-grade glioma

US FDA grants accelerated approval to Day One Biopharma’s tovorafenib to treat relapsed or refractory BRAF-altered paediatric low-grade glioma: Brisbane, California Thursday, Ap ... read more

Day One’s Kinase Inhibitor Gets FDA Accelerated Approval for Pediatric Brain Tumor

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric ... read more

Buy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemda

Day One Biopharmaceuticals (DAWN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ... read more

Take-at-home brain cancer treatment for children will soon be available on NHS

The combination treatment, which is given at home rather than in hospital, works by targeting the proteins made by the altered BRAF gene that is responsible for uncontrollable tumour growth. read more

Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment

Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment ... read more

Melanomas resist drugs by 'breaking' genes

A study has disentangled the mechanisms behind one of the ways melanoma cancer cells develop resistance to treatment. The study found that, in response to some drugs, melanomas can 'break' parts of ... read more